Recombinant DNA derived monomeric insulin analogue: Comparison with soluble human insulin in normal subjects

Abstract

Objective - To compare the rate of absorption from subcutaneous tissue and the resulting hypoglycaemic effect of iodine-125 labelled soluble human insulin and a monomeric insulin analogue derived by recombinant DNA technology. Design - Single blind randomised comparison of equimolar doses of 125I labelled soluble human insulin and insulin analogue. Setting - Study in normal people at a diabetes research unit and a university department of medical physics. Subjects - Seven healthy male volunteers aged 20-39 not receiving any other drugs. Interventions - After an overnight fast and a basal period of one hour two doses (0.05 and 0.1 U/kg) of 125I labelled soluble human insulin and insulin analogue were injected subcutaneously into the anterior abdominal wall on four separate days. End point - To find a fast acting insulin for meal related requirements in insulin dependent diabetics. Measurements and main results - Residual radioactivity at the injection site was measured continuously for the first two hours after injection of the 1265I labelled preparations and thereafter for five minutes simultaneously with blood sampling. Frequent venous blood samples were obtained over six hours for determination of plasma immunoreactive insulin, insulin analogue, glucose, and glucagon values. Time to 50% of initial radioactivity at the injection site for the insulin analogue compared with soluble insulin was 61 v 135 minutes (p < 0.05) with 0.05 U/kg and 67 v 145 minutes (p < 0.001) with 0.1 U/kg. Concentration in plasma increased faster after the insulin analogue compared with soluble insulin, resulting in higher plasma concentrations between 10 and 150 minutes (0.001 < p <0.05) after 0.05 U/kg and between 40 and 360 minutes (0.001 < p <0.05) after 0.1 U/kg. The hypoglycaemic response to insulin analogue was a plasma glucose nadir at 60 minutes with both doses compared with 90 and 120 minutes with soluble insulin at 0.5 and 0.1 U/kg respectively. The response of glucagon substantiated the earlier and more dramatic hypoglycaemic effect with the insulin analogue. Conclusions - The much faster absorption from subcutaneous tissue of the disubstituted monomeric insulin analogue compared with soluble insulin suggests that the analogue may be a potential candidate for rapid insulin delivery after subcutaneous bolus injection.